Ubs Group Ag Infla Rx N.V. Put Options Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IFRX
# of Institutions
32Shares Held
17.5MCall Options Held
32.7KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY6.48MShares$5.38 Million0.18% of portfolio
-
683 Capital Management, LLC New York, NY2.48MShares$2.05 Million0.15% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.97MShares$1.64 Million0.03% of portfolio
-
Eversept Partners, LP New York, NY1.64MShares$1.36 Million0.13% of portfolio
-
Woodline Partners LP San Francisco, CA751KShares$623,5510.0% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $36.7M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...